Une plateforme technologique de libération ciblée
Indication
Cancer
Stade de développement
Préclinique
Brevets
Applications aux É.-U. et PCT (Traité de Coopération en matière de Brevets) déposés
Partenaire
Disponible pour octroi de licence
Cancer - Technologie de libération NGR
Références scientifiques
Articles
- Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63(21):7400-7409
- Curnis, F., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002 62(3):867-874
Présentations
- Garde, S., et al. TVT-Dox: in vivo efficacy and in vitro molecular mechanism of action. AACR 2007, Los Angeles, California, USA, April 14-18, 2007.
- Wu, J.J., et al. A novel dual-targeting drug for the solid tumors and their vasculature. 2006 Miami Nature Biotechnology Winter Symposium Angiogenesis in Cancer and Vascular Disease, Miami Beach, Floride, Février 2006.
- Meyer, O., et al. Preclinical efficacy of tumor vasculature targeted liposomal doxorubicin. Royal Society of Canada (RSC)/ Korean Academy of Science and Technology (KAST) 3rd Bilateral Symposium: Drug Delivery Systems, Vancouver, Canada, July 2005.
- Meyer, O.,et al. Assay methods for binding NGR-targeted liposomal doxorubicin using cells expressing the angiogenic marker CD13. Lipids, Liposomes & Biomembranes, new technologies, UBC, Vancouver, Canada, Juillet 2005.